Skip to Content

Join the 'Postherpetic Neuralgia' group to help and get support from people like you.

Postherpetic Neuralgia News

Shingles Vaccine Appears to Cut Odds of Long-Term Pain

Posted 4 Jun 2015 by Drugs.com

TBD, 2015 – Even when shingles vaccination does not prevent the disease, it reduces the risk of long-term pain that can occur as a complication of the condition, according to a new study. Although the U.S. Advisory Council on Immunization Practices recommends shingles vaccination for people 60 and older, vaccination rates remain low, the researchers say. "Hopefully, this study will encourage more people to get vaccinated in order to reduce the long-term pain and potential disability associated with shingles," said lead author Hung Fu Tseng, a researcher with Kaiser Permanente Southern California. Tseng's team analyzed the medical records of 2,400 people in Southern California over age 60 who developed shingles. Some had been vaccinated against the disease. Among vaccinated patients, just over 4 percent of women and 6 percent of men developed long-term pain (post-herpetic neuralgia, or ... Read more

Related support groups: Persisting Pain, Shingles, Postherpetic Neuralgia, Varicella-Zoster, Varicella Virus Vaccine, Measles Virus Vaccine/Mumps Virus Vaccine/Rubella Virus Vaccine/Varicella Virus Vaccine, ProQuad, Varivax, Varicella-Zoster - Prophylaxis

GSK and XenoPort Receive FDA Approval for Horizant for Postherpetic Neuralgia

Posted 7 Jun 2012 by Drugs.com

LONDON & RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun 7, 2012 - GlaxoSmithKline plc and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. The efficacy and safety of Horizant for the management of PHN was evaluated in a single 12-week principal efficacy trial, plus two supportive studies that all met their respective primary endpoints. The three clinical studies involved 574 adult patients from the US, Canada and Germany. The recommended dosage for the management of PHN in adults is 600 mg twice daily. Treatment should be initiated at a dose of 600 mg in the morning for three days followed by 600 mg twice daily (1,200 mg/day) beginning on day four. Doses must be adjusted in patients with ... Read more

Related support groups: Gabapentin, Postherpetic Neuralgia, Horizant

Drug Combo May Offer Best Relief for Nerve Pain

Posted 16 Jul 2010 by Drugs.com

TUESDAY, Sept. 29 – People with nerve pain respond better to a combination treatment using the anticonvulsant gabapentin and antidepressant nortriptyline than to treatment with either drug alone, according to Canadian researchers. The study findings suggest that combination treatment could be used to help people who only partially respond to one drug or the other. Nerve, or neuropathic, pain – which affects 2 to 3 percent of the population – is "initiated or caused by a primary lesion or dysfunction in the nervous system," according to a news release from The Lancet, which is publishing the study online Sept. 29. Conditions that cause neuropathic pain include nerve problems in the spine, diabetes-related nerve damage and postherpetic neuralgia (PHN), which is nerve pain caused by the varicella zoster virus that can follow an outbreak of shingles. The study included 56 people with PHN ... Read more

Related support groups: Gabapentin, Neuralgia, Neurontin, Nortriptyline, Diabetic Neuropathy, Diabetic Nerve Damage, Persisting Pain, Shingles, Postherpetic Neuralgia, Pamelor, Gabarone, Aventyl HCl

NeurogesX Receives FDA Approval of Qutenza (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)

Posted 2 Dec 2009 by Drugs.com

SAN MATEO, Calif., Nov. 16 /PRNewswire-FirstCall/ – NeurogesX, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles. Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced pain following a single one-hour application. It is the first product from NeurogesX to be approved by the FDA. "PHN can be an excruciatingly painful condition that can affect many aspects of a patient's quality of life. Despite a variety of medications for pain, undesirable side effects often limit their use and therefore, the treatment of PHN ... Read more

Related support groups: Postherpetic Neuralgia

Ask a Question

Further Information

Related Condition Support Groups

Neuralgia

Related Drug Support Groups

gabapentin, Lyrica, Neurontin, clonidine, nortriptyline, pregabalin, Lidoderm, Gralise, capsaicin, view more... Catapres, Horizant, gabapentin enacarbil, Capzasin, Zostrix, Pain Doctor, Capzasin-HP, Icy Hot PM, Capzasin-P, Sloan's Liniment, Qutenza, Drs Cream, Trixaicin, Gabarone, Capzasin Back and Body, Zostrix Neuropathy, CidalEaze, LidoRxKit, R-Gel, Pain-X, No Pain-HP, Zostrix Sports, Trixaicin HP, RT Capsin, Dolorac, Zostrix-HP, Capsin, Capsicum Oleoresin, Axsain, Salonpas Gel-Patch, Castiva Warming, GNP Capsaicin